Schonfeld Strategic Advisors LLC Has $29.88 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Schonfeld Strategic Advisors LLC raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 355.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 127,000 shares of the biopharmaceutical company’s stock after purchasing an additional 99,133 shares during the quarter. Schonfeld Strategic Advisors LLC owned 0.10% of Alnylam Pharmaceuticals worth $29,884,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ALNY. Larson Financial Group LLC lifted its position in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 73 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $33,000. OFI Invest Asset Management acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at $35,000. Versant Capital Management Inc boosted its position in Alnylam Pharmaceuticals by 77.6% during the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 83 shares during the last quarter. Finally, IFP Advisors Inc raised its stake in shares of Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 47 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several recent research reports. Scotiabank boosted their target price on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 31st. HC Wainwright reissued a “buy” rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Sanford C. Bernstein dropped their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a “buy” rating and a $353.00 price target for the company. Finally, Morgan Stanley dropped their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating on the stock in a research note on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $315.58.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the transaction, the chief executive officer now owns 81,526 shares in the company, valued at approximately $20,802,989.42. The trade was a 1.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the transaction, the chief financial officer now owns 32,786 shares in the company, valued at approximately $8,366,003.62. This trade represents a 2.86 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 7,392 shares of company stock worth $1,875,627. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 1.3 %

Shares of ALNY opened at $254.85 on Tuesday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The company has a 50-day moving average price of $247.46 and a two-hundred day moving average price of $255.63. The stock has a market cap of $33.15 billion, a price-to-earnings ratio of -117.44 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 12 month low of $143.50 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.